Active Endothelial Cell Specific Molecule 1 (ESM1) Homo sapiens (Human) Active protein

Endocan

Add to Cart Distributors
Overview
Properties
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point6.7
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Endothelial Cell Specific Molecule 1 (ESM1) Packages (Simulation)
  • Active Endothelial Cell Specific Molecule 1 (ESM1) Packages (Simulation)
  • Active Endothelial Cell Specific Molecule 1 (ESM1) Gene sequencing
  • APC463Hu01.jpg SDS-PAGE
  • Active Endothelial Cell Specific Molecule 1 (ESM1) Figure. Western Blot; Sample: Recombinant ESM1, Human.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Endothelial cell-specific molecule 1 (ESM1) is a proteoglycan secreted by endothelial cells (primarily in the human lung and kidney tissues) and its mRNA expression is regulated by inflammatory cytokines. Endocan expression, which detected in various epithelia and adipocytes has been shown to be upregulated by vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), TNF alpha, IL1 beta, or lipopolysaccharide and downregulated by IFN gamma. Genetically engineered cells overexpressing ESM1 induce tumor formation, implying that ESM1 might be involved in the pathophysiology of tumor growth in vivo. Besides, Lymphocyte Function Associated Antigen 1 Alpha (LFA1a) has been identified as an interactor of ESM1, thus a binding ELISA assay was conducted to detect the interaction of recombinant human ESM1 and recombinant human LFA1a. Briefly, ESM1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to LFA1a-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti- ESM1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of of ESM1 and LFA1a was shown in Figure 1, and this effect was in a dose dependent manner.

Usage

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantationPubMed: 22608803
  • Endocan is useful biomarker of survival and severity in sepsis.Pubmed: 24769132
  • Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromesPubmed:25211383
  • Endocan is useful biomarker of survival and severity in sepsisPubmed:24769132
  • Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus ErythematosusPubMed: 26614790
  • Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control studyJournal:-102
  • Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension.pubmed:27912147
  • Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancerpubmed:28514746
  • Changes in Endocan Levels and Blood Coagulation in HIV InfectionDOI: 10.13005/bpj/1082
  • A novel role of endocan in alleviating LPS-induced acute lung injuryPubmed:29627442
  • Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction?Pubmed:30054863
  • Serum Level of Endothelial Cell-Specific Molecule-1 (ESM-1) as a New Potential Biomarker for Rheumatoid Arthritis Disease ActivityDoi: 10.2174/1874312901812010189
  • Downregulation of ENDOCAN in myeloid leukemia cells inhibits proliferation and promotes apoptosis by suppressing nuclear factor‑κB activityPubmed: 30816462
  • Endothelial biomarkers in the light of new sepsis definitionPubmed: 30920847
  • Risk stratification and prognostic evaluation of endothelial cell‑specific molecule1, von Willebrand factor, and a disintegrin‑like and metalloprotease with …
  • A novel marker relationship between carotid intima–media thickness and disease activity score-28 in patients with rheumatoid arthritis: human endothelial cell …Pubmed: 31655533
  • Role of Ascitic Endocan Levels in the Diagnosis of Spontaneous Bacterial Peritonitis in Decompensated CirrhosisPubmed: 32364003
  • Comparison of the maternal serum endocan levels in preterm premature rupture of membrane and normal pregnancy34109715
  • The relationship between serum endocan levels with the presence of contrast-induced nephropathy in patients undergoing coronary angiography

Recommend products